The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Prognostic markers in MCL and the value of CAR-T therapy in treating high-risk disease
Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses prognostic markers and high-risk features in mantle cell lymphoma (MCL), including p53 mutation, high-Ki 67, and blastoid morphology. Dr Eyre also comments on the importance of planning treatment with CAR-T therapy in advance for patients with high-risk disease, and the promising responses obtained with the use of CAR-T therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Roche: Education Honorarium, Advisory Board Honorarium, Travel to scientific conferences
Gilead: Honorarium; Research support; Travel to scientific conferences
KITE: Education Honorarium, Advisory Board Honorarium,
Janssen: Honorarium
Abbvie: Honorarium; Travel to scientific conferences
AstraZeneca: Honorarium, Research funding, Travel to scientific conferences
Loxo Oncology: Advisory Board Honorarium, Trial steering committee
Beigene: Advisory Board Honorarium, Research funding
Incyte: Advisory Board Honorarium
Secura Bio: Advisory Board Honorarium
